GKOS - Glaukos Corporation

NYSE - NYSE Delayed Price. Currency in USD
80.54
+3.03 (+3.91%)
At close: 4:02PM EDT

80.54 0.00 (0.00%)
After hours: 4:17PM EDT

Stock chart is not supported by your current browser
Previous Close77.51
Open77.31
Bid75.50 x 1100
Ask0.00 x 800
Day's Range77.31 - 82.24
52 Week Range26.75 - 82.24
Volume606,435
Avg. Volume398,545
Market Cap2.912B
Beta (3Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.25
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    Pivotal Trial Results for Glaukos’ iStent inject® Published in Leading Ophthalmic Journal

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investigational Device Exemption (IDE) pivotal trial results for its next-generation iStent inject® Trabecular Micro-Bypass System have been published in Ophthalmology. Results of the iStent inject prospective, randomized, controlled, multicenter clinical trial, which included 505 mild-to-moderate primary open-angle glaucoma (POAG) subjects from 41 investigational sites, formed the basis for Food & Drug Administration approval of the device in June 2018.

  • Business Wire8 days ago

    Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society Annual Meeting on March 14-17, 2019 at the Marriott ...

  • When Should You Buy Glaukos Corporation (NYSE:GKOS)?
    Simply Wall St.8 days ago

    When Should You Buy Glaukos Corporation (NYSE:GKOS)?

    Glaukos Corporation (NYSE:GKOS), which is in the medical equipment business, and is based in United States, saw a significant share price rise of over 20% in the past couple ofRead More...

  • Business Wire9 days ago

    International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent® Implantation in Combination with Cataract Surgery

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent® Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean intraocular pressure (IOP) to 14.7 mmHg after five years of follow-up.

  • Why Glaukos Stock Jumped 16.3% in February
    Motley Fool15 days ago

    Why Glaukos Stock Jumped 16.3% in February

    Shares of this mid-cap ophthalmic medical tech and pharmaceutical company have soared 111% over the last year.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Glaukos Corp NYSE:GKOSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for GKOS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding GKOS totaled $199 million. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of GKOS earnings conference call or presentation 27-Feb-19 9:30pm GMT

    Q4 2018 Glaukos Corp Earnings Call

  • Glaukos Corp (GKOS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool22 days ago

    Glaukos Corp (GKOS) Q4 2018 Earnings Conference Call Transcript

    GKOS earnings call for the period ending December 31, 2018.

  • Business Wire22 days ago

    Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2018.

  • Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline
    Zacks29 days ago

    Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline

    Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wirelast month

    Glaukos Corporation to Release Fourth Quarter and Full Year 2018 Financial Results after Market Close on February 27

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release fourth quarter and full year 2018 financial results after the market close on Wednesday, February 27, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 27, 2019.

  • Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares This Year?
    Simply Wall St.2 months ago

    Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Tamarack Capital Management’s Return, AUM, and Holdings
    Insider Monkey2 months ago

    Tamarack Capital Management’s Return, AUM, and Holdings

    Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]

  • Hedge Funds Are Betting On Glaukos Corporation (GKOS)
    Insider Monkey3 months ago

    Hedge Funds Are Betting On Glaukos Corporation (GKOS)

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • Business Wire3 months ago

    Glaukos Announces Participation in J.P. Morgan Healthcare Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 9:30 a.m. PST in San Francisco. Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

  • Business Wire3 months ago

    Glaukos iStent inject® Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burden, According to New Study

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that a single-site international study of glaucoma subjects recently published in Ophthalmology and Therapy showed that the iStent inject® Trabecular Micro-Bypass System, combined with cataract surgery, achieved a 37% reduction in mean intraocular pressure (IOP) to 14.3 mmHg after three years of follow-up.

  • GlobeNewswire4 months ago

    Consolidated Research: 2018 Summary Expectations for The Hackett Group, Green Plains, Malibu Boats, Hawaiian Electric Industries, Iridium Communications, and Glaukos — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Is Glaukos Corporation’s (NYSE:GKOS) CEO Pay Fair?
    Simply Wall St.4 months ago

    Is Glaukos Corporation’s (NYSE:GKOS) CEO Pay Fair?

    Thomas Burns became the CEO of Glaukos Corporation (NYSE:GKOS) in 2002. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll look Read More...

  • Business Wire4 months ago

    Glaukos Announces Participation in Piper Jaffray Healthcare Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 10:00 a.m. EST in New York City. Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.